New Biosimilar Approvals for Myeloid Growth Factors and Anemia.
Publication
, Conference
Lyman, GH
Published in: J Natl Compr Canc Netw
May 1, 2019
Biosimilars are here to stay, but whether they will enjoy widespread uptake remains to be seen. The FDA sets a high bar for approval of biosimilar products, yet many clinicians remain skeptical about the efficacy and safety of these agents. Favorable experience with >30 biosimilars in Europe provides some reassurance that these agents are safe and effective and can be substituted for the reference product.
Duke Scholars
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
May 1, 2019
Volume
17
Issue
5.5
Start / End Page
622 / 624
Location
United States
Related Subject Headings
- United States
- Oncology & Carcinogenesis
- Humans
- Drug Approval
- Disease Management
- Colony-Stimulating Factors
- Biosimilar Pharmaceuticals
- Anemia
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H. (2019). New Biosimilar Approvals for Myeloid Growth Factors and Anemia. In J Natl Compr Canc Netw (Vol. 17, pp. 622–624). United States. https://doi.org/10.6004/jnccn.2019.5016
Lyman, Gary H. “New Biosimilar Approvals for Myeloid Growth Factors and Anemia.” In J Natl Compr Canc Netw, 17:622–24, 2019. https://doi.org/10.6004/jnccn.2019.5016.
Lyman GH. New Biosimilar Approvals for Myeloid Growth Factors and Anemia. In: J Natl Compr Canc Netw. 2019. p. 622–4.
Lyman, Gary H. “New Biosimilar Approvals for Myeloid Growth Factors and Anemia.” J Natl Compr Canc Netw, vol. 17, no. 5.5, 2019, pp. 622–24. Pubmed, doi:10.6004/jnccn.2019.5016.
Lyman GH. New Biosimilar Approvals for Myeloid Growth Factors and Anemia. J Natl Compr Canc Netw. 2019. p. 622–624.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
May 1, 2019
Volume
17
Issue
5.5
Start / End Page
622 / 624
Location
United States
Related Subject Headings
- United States
- Oncology & Carcinogenesis
- Humans
- Drug Approval
- Disease Management
- Colony-Stimulating Factors
- Biosimilar Pharmaceuticals
- Anemia
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis